| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/17/2001 | EP1144600A2 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 10/17/2001 | EP1144420A1 Sulfated phosphatidylinositols, their preparation and use |
| 10/17/2001 | EP1144377A1 Oxetanone derivatives |
| 10/17/2001 | EP1144065A1 Apparatus and process for preparing crystalline particles |
| 10/17/2001 | EP1144013A1 Lactone bearing absorbable polymers |
| 10/17/2001 | EP1144012A1 Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery |
| 10/17/2001 | EP1144011A2 Prodrug compounds and process for preparation thereof |
| 10/17/2001 | EP1144010A2 Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28 |
| 10/17/2001 | EP1144009A2 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| 10/17/2001 | EP1143991A2 Inhibitors of h+k+ -atpase |
| 10/17/2001 | EP1143990A2 Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections |
| 10/17/2001 | EP1143985A2 Use of lactobacillus salivarius |
| 10/17/2001 | EP1143978A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 10/17/2001 | EP1143973A2 Compositions having improved stability |
| 10/17/2001 | EP1143968A2 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 10/17/2001 | EP1143963A1 Multiparticulate bisoprolol formulation |
| 10/17/2001 | EP1143962A1 Parenteral solution of propofol (2,6-diisoprophylphenol) and 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol as a solvent |
| 10/17/2001 | EP1143950A2 Topical application products |
| 10/17/2001 | EP1143947A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 10/17/2001 | EP1143940A2 Compositions and methods for mucosal delivery |
| 10/17/2001 | EP1143938A2 Phinan |
| 10/17/2001 | EP1143936A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN $g(a)-ANTAGONIST |
| 10/17/2001 | EP1143935A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 10/17/2001 | EP1143933A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 10/17/2001 | EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers |
| 10/17/2001 | EP1143931A1 Pulmonary drug delivery |
| 10/17/2001 | EP1143930A2 Pharmaceutical formulation of fluticasone propionate |
| 10/17/2001 | EP1143929A1 BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
| 10/17/2001 | EP1143927A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 10/17/2001 | EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system |
| 10/17/2001 | EP1143913A1 Preparation for dental treatment |
| 10/17/2001 | EP1143896A1 Methods of hydrating mucosal surfaces |
| 10/17/2001 | EP1143806A2 Method for increasing pet activity |
| 10/17/2001 | EP1143796A1 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| 10/17/2001 | EP1007097B1 Formulation of stabilised cationic transfection agent(s)/nucleic acid particles |
| 10/17/2001 | EP0999841B1 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| 10/17/2001 | EP0841930B1 Stable solid formulation of enalapril salt and process for preparation thereof |
| 10/17/2001 | EP0804165B1 Solid medicament form with active agent distributed in polymer material |
| 10/17/2001 | EP0769965B1 Aqueous risperidone formulations |
| 10/17/2001 | EP0759744B1 Narcotic containing aerosol formulation |
| 10/17/2001 | EP0664696B2 Sustained release compositions for treating periodontal disease |
| 10/17/2001 | EP0633784B2 Hepatitis vaccins containing 3-0 deacylated monophosphoryl lipid A |
| 10/17/2001 | CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof |
| 10/17/2001 | CN1317977A Dry powder active agent pulmonary delivery |
| 10/17/2001 | CN1317973A Prepns. for immunotherapy for cancer having bacterial somatic constituent as active ingredient |
| 10/17/2001 | CN1317967A Protein formulations |
| 10/17/2001 | CN1317959A Multiple unit controlled non-independent release pharmaceutical preparations and method for preparing same |
| 10/17/2001 | CN1317342A Eye preparation |
| 10/17/2001 | CN1317310A Method of preparing solid state creatine dosage and creatine dosage by same |
| 10/17/2001 | CN1317309A Instant oral medincinal preparation |
| 10/17/2001 | CN1073119C Method and compsns. for dry powder formulation of interferons |
| 10/17/2001 | CN1073113C Comptothetic derivatives, its prepn. process and use |
| 10/17/2001 | CN1072966C Prepn. of hollow microcapsules |
| 10/17/2001 | CN1072965C Local medicinal compsns. with increasing function of passing skin |
| 10/17/2001 | CN1072964C Colon-specific drug release system |
| 10/17/2001 | CN1072963C Vaccine compsns. |
| 10/16/2001 | USRE37410 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| 10/16/2001 | US6303656 For therapy and/or prophylaxis of human skin, mucous membranes and/or keratin fibers, in particular for moisturizing the skin and for treatment of dry skin |
| 10/16/2001 | US6303631 Water-soluble eye drop |
| 10/16/2001 | US6303626 Pharmaceutical formulations in dry form for the oral administration of a cyclic quaternary ammonium compound |
| 10/16/2001 | US6303607 Administering sustained release pharmaceutical dosage form including ranolazine, ph-dependent and ph-independent binders to human suffering from variant or excercise-induced angina |
| 10/16/2001 | US6303585 Cross-linked polysaccharide drug carrier |
| 10/16/2001 | US6303584 Can be used to inhibit cell adhesion, and to inhibit infection or inflammation, as adjuvants to inhibit metastasis |
| 10/16/2001 | US6303582 Compositions and methods for nucleic acid delivery to the lung |
| 10/16/2001 | US6303574 Scr SH3 binding peptides and methods of isolating and using same |
| 10/16/2001 | US6303573 Heart homing peptides and methods of using same |
| 10/16/2001 | US6303569 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| 10/16/2001 | US6303379 Transfected cells for use in treatment of genetic disorder |
| 10/16/2001 | US6303347 Vaccines |
| 10/16/2001 | US6303312 Modifying cell phenotype; medical research and therapy |
| 10/16/2001 | US6303167 Mixing silica and liquid mixed tocopherol to produce dry free-flowing powders |
| 10/16/2001 | US6303157 Extracts of kava-kava |
| 10/16/2001 | US6303151 Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| 10/16/2001 | US6303150 Method for producing nanocapsules with crosslinked protein-based walls nanocapsules thereby obtained and cosmetic, pharmaceutical and food compositions using same |
| 10/16/2001 | US6303149 Method for the preparation of oxide microcapsules loaded with functional molecules and the products obtained thereof |
| 10/16/2001 | US6303148 Process for the preparation of a controlled release system |
| 10/16/2001 | US6303137 For applying bioactive substances |
| 10/16/2001 | US6303132 Administering progesterone using EMU oil |
| 10/16/2001 | US6303127 Treatment of disease states |
| 10/16/2001 | US6303113 Preservative chlorobutanol, wherein said human protein has erythropoietin-like activity or granulocyte-colony stimulating factor-like activity |
| 10/16/2001 | US6303103 1,1,1,2-tetrafluoroethane as propellant; inhalants. |
| 10/16/2001 | US6303100 Methods for inhibiting the formation of potential endoleaks associated with endovascular repair of abdominal aortic aneurysms |
| 10/16/2001 | CA2181156C Macroencapsulated secretory cells |
| 10/16/2001 | CA2152615C Atovaquone pharmaceutical compositions |
| 10/16/2001 | CA2137296C Phospholipid derivative and reactive vesicle-forming agent |
| 10/12/2001 | CA2318665A1 Method of treating onychomycosis |
| 10/11/2001 | WO2001075110A2 Mucin-1 specific binding members and methods of use thereof |
| 10/11/2001 | WO2001074928A1 Process for the preparation of protein-based hydrogels |
| 10/11/2001 | WO2001074917A1 Hydrophilic polymers, pressure sensitive adhesives and coatings |
| 10/11/2001 | WO2001074915A1 Ampholytic polymer dispersion composition and method of use |
| 10/11/2001 | WO2001074849A2 Binding peptides for carcinoembryonic antigen (cea) |
| 10/11/2001 | WO2001074780A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 10/11/2001 | WO2001074448A1 Stable thyroid hormone preparations and method of making same |
| 10/11/2001 | WO2001074431A2 Dispensing devices and liquid formulations |
| 10/11/2001 | WO2001074402A2 Camptothecin conjugates |
| 10/11/2001 | WO2001074401A2 Camptothecin complexes |
| 10/11/2001 | WO2001074400A1 Transporters and drug delivery system by using the same |
| 10/11/2001 | WO2001074399A1 Drugs retained in target tissue over long time |
| 10/11/2001 | WO2001074395A2 Amiodarone-containing parenteral solution |
| 10/11/2001 | WO2001074387A1 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery |